RecruitingNot ApplicableNCT07039201

A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC)

An Exploratory Clinical Study on the Safety and Efficacy of Autologous Chimeric Antigen Receptor T Cells Targeting Glypican-3 (CG-102-12C) in the Treament of Advanced Hepatocellular Carcinoma

Sponsor

Zhejiang University

Enrollment

12 participants

Start Date

Jun 28, 2025

Study Type

INTERVENTIONAL

Conditions

Advanced Hepatocellular Carcinoma (HCC)

Summary

This study is a single-centre, single-arm, open-label, dose-escalation exploratory study with single-dose administration. Its objective is to evaluate the safety, tolerability, dose, anti-tumor efficacy, and pharmacokinetic characteristics of CG-102-12C in the participants with GPC3-positive advanced hepatocellular carcinoma who previously received adequate but uneffective systemic standard treatments.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new drug called CG-102-12C in patients with advanced liver cancer (hepatocellular carcinoma) whose tumors express a protein called Glypican-3 (GPC3), which is found on many liver cancer cells. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed advanced liver cancer (HCC) - Your tumor tests positive for the GPC3 protein - You have tried at least one prior treatment that did not work **You may NOT be eligible if...** - Your liver cancer is at an early stage eligible for surgery - You have severe liver disease (Child-Pugh C) - You have uncontrolled infections or other cancers Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.